Company intelligence / Profile preview
ISA Pharmaceuticals
Oegstgeest, South Holland, Netherlandsisa-pharma.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
01
Overview
Lead asset ISA101b is in late-stage clinical trials for HPV16-induced cancers in collaboration with Regeneron. ISA104 for chronic Hepatitis B is in Phase 1 clinical testing (HEB-PEP trial). A Phase 1 study using AMPLIVANT adjuvant and SLP technology demonstrated favorable safety profile and strong immune response.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Synthetic Long Peptide (SLP) immunotherapeuticsAMPLIVANT-adjuvanted vaccines
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →03
Partnerships
RegeneronErasmus MC
Beyond the preview
Go deeper on ISA Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISA Pharmaceuticals.